Vorolanib Intravitreal Insert Shows Promise for Durable DME Treatment
Overview
Phase 2 VERONA trial data demonstrate that the vorolanib intravitreal insert (EYP-1901) provides extended durability and meaningful visual acuity improvements in diabetic macular edema (DME) compared to aflibercept. The sustained-release tyrosine kinase inhibitor (TKI) insert showed a favorable safety profile and potential to reduce treatment burden.
Background
Diabetic macular edema is a leading cause of vision loss in diabetic patients, commonly treated with anti-VEGF injections requiring frequent administration. Vorolanib, a TKI delivered via a sustained-release intravitreal insert, offers a novel mechanism by inhibiting all VEGF receptors intracellularly, potentially complementing existing therapies. The VERONA phase 2 trial evaluated the efficacy and safety of EYP-1901 compared to aflibercept, focusing on time to first supplemental treatment and visual outcomes.
Data Highlights
| Parameter | Vorolanib 2.7 mg | Aflibercept |
|---|---|---|
| Supplement-free patients at 24 weeks | 73% | 50% |
| Mean BCVA improvement at 24 weeks | ~7 letters (10.1 letters excluding outlier) | 7.3 letters |
| Central subfield thickness (CST) reduction | >75 µm decrease | Not specified |
Key Findings
- VERONA trial met its primary endpoint: vorolanib extended time to first supplemental anti-VEGF injection compared to aflibercept.
- Single injection of EYP-1901 resulted in clinically meaningful BCVA gains (~7 letters) at 24 weeks, with improved retinal anatomy.
- 73% of patients in the vorolanib 2.7 mg arm remained free of supplemental treatment through 24 weeks versus 50% in the aflibercept arm.
- Vorolanib’s intracellular TKI mechanism inhibits all VEGF receptors, differing from extracellular VEGF-A blockade by anti-VEGF agents.
- The intravitreal insert delivers drug with zero-order kinetics, providing stable release over at least 6 months and potentially reducing treatment burden.
- Safety profile across >190 patients showed no ocular or systemic serious adverse events related to vorolanib insert.
Clinical Implications
Vorolanib intravitreal insert may offer a durable treatment option for DME, reducing the frequency of injections and associated patient burden. Its distinct mechanism could complement current anti-VEGF therapies, potentially improving outcomes. Ongoing phase 3 trials will clarify its role and optimal dosing schedules in clinical practice.
Conclusion
The phase 2 VERONA data support vorolanib intravitreal insert as a promising, durable therapy for DME with meaningful visual gains and a favorable safety profile. Further phase 3 studies are underway to confirm these findings and establish its place in treatment paradigms.
References
- EyePoint Pharmaceuticals 2024 -- Phase 2 VERONA Trial Results for Vorolanib in DME
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.